Tibet Haisco Pharmaceutical Co. Ltd. has prepared new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to androgen receptor variant 7 (AR-v7)-targeting moiety.

Work at Nextgen Bioscience Co. Ltd. has led to the development of purine derivatives acting as hypoxia-inducible factor 1α (HIF-1α) inhibitors.

AC Immune SA has identified pyrrolotriazine and imidazotriazine derivatives acting as NLRP3 inflammasome inhibitors.

A Biogen Inc. patent describes new non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of stroke, psoriasis, arthritis, pain, silicosis, alopecia, inflammatory disorders and autoimmune diseases.

Humanwell Healthcare (Group) Co. Ltd. has described heterocyclic fused benzene ring compounds acting as dual microtubule destabilizers (tubulin polymerization inhibitors) and proto-oncogene tyrosine-protein kinase Src (SRC; SRC1) inhibitors.

Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) and the University of Michigan have prepared and tested new protein cereblon (CRBN) ligands expected to be useful for the treatment of cancer and inflammatory disorders.

Muna Therapeutics ApS has disclosed new triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, type 2 diabetes, obesity, metabolic dysfunction-associated steatotic liver disease, neurodegenerative and inflammatory bowel disease, among others.

Janssen Pharmaceutica NV researchers have identified new compounds for the treatment of SARS-CoV-2 infection (COVID-19).

A recent Vividion Therapeutics Inc. patent describes Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the treatment of cancer.